PRESCRIPTION DRUG PRICE REVIEW COMMISSION
Executive Summary
PRESCRIPTION DRUG PRICE REVIEW COMMISSION could be part of a National Health Board established under the Clinton Administration's proposed national health care reform legislation. If the administration's proposal calls for review of pharmaceutical prices, the review reportedly will be either one of the functions of the National Health Board or the specific role of a subgroup of the board. Pharmaceutical companies oppose drug price review as conflicting with the free-market philosophy of managed competition, and the industry has lobbied against establishment of a price review commission. However, the National Health Board is a key element of the managed competition concept. Although such a board ultimately may not be authorized to conduct drug price reviews, one is certain to be appointed if anything resembling the Clinton Administration's plan is adopted by Congress. Under the proposal, which might not be released until September, the board would be appointed by the President and charged primarily with reviewing health plan benefits and determining standards for outcomes research and performance measures to help individuals compare competing health plans. Collecting and providing information to consumers necessarily will involve oversight of health care provider practices, and review of the expense of specific therapies, particularly new, higher-priced treatments, could be a natural extension of that authority. If pharmaceutical prices are subject to review under the reformed health care system, industry representatives hope at least to limit the nature of the review to a strictly monitoring capacity and to narrow its scope to new products whose reviews were considered a priority by FDA.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth